JP2020510704A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510704A5
JP2020510704A5 JP2019571809A JP2019571809A JP2020510704A5 JP 2020510704 A5 JP2020510704 A5 JP 2020510704A5 JP 2019571809 A JP2019571809 A JP 2019571809A JP 2019571809 A JP2019571809 A JP 2019571809A JP 2020510704 A5 JP2020510704 A5 JP 2020510704A5
Authority
JP
Japan
Prior art keywords
cell
cancer
composition
composition according
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019571809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510704A (ja
JP7277388B2 (ja
Filing date
Publication date
Priority claimed from GBGB1704084.1A external-priority patent/GB201704084D0/en
Priority claimed from GBGB1721603.7A external-priority patent/GB201721603D0/en
Application filed filed Critical
Priority claimed from PCT/GB2018/050652 external-priority patent/WO2018167486A1/en
Publication of JP2020510704A publication Critical patent/JP2020510704A/ja
Publication of JP2020510704A5 publication Critical patent/JP2020510704A5/ja
Priority to JP2023076631A priority Critical patent/JP2023103318A/ja
Application granted granted Critical
Publication of JP7277388B2 publication Critical patent/JP7277388B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019571809A 2017-03-15 2018-03-14 方法 Active JP7277388B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023076631A JP2023103318A (ja) 2017-03-15 2023-05-08 方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1704084.1A GB201704084D0 (en) 2017-03-15 2017-03-15 Method
GB1704084.1 2017-03-15
GB1721603.7 2017-12-21
GBGB1721603.7A GB201721603D0 (en) 2017-12-21 2017-12-21 Method
PCT/GB2018/050652 WO2018167486A1 (en) 2017-03-15 2018-03-14 Method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023076631A Division JP2023103318A (ja) 2017-03-15 2023-05-08 方法

Publications (3)

Publication Number Publication Date
JP2020510704A JP2020510704A (ja) 2020-04-09
JP2020510704A5 true JP2020510704A5 (https=) 2021-04-22
JP7277388B2 JP7277388B2 (ja) 2023-05-18

Family

ID=61868533

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019571809A Active JP7277388B2 (ja) 2017-03-15 2018-03-14 方法
JP2023076631A Withdrawn JP2023103318A (ja) 2017-03-15 2023-05-08 方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023076631A Withdrawn JP2023103318A (ja) 2017-03-15 2023-05-08 方法

Country Status (8)

Country Link
US (2) US11427645B2 (https=)
EP (1) EP3595705A1 (https=)
JP (2) JP7277388B2 (https=)
KR (2) KR20230166145A (https=)
CN (1) CN110678197A (https=)
AU (2) AU2018235130B2 (https=)
CA (1) CA3056542A1 (https=)
WO (1) WO2018167486A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11126040B2 (en) 2012-09-30 2021-09-21 Optica Amuka (A.A.) Ltd. Electrically-tunable lenses and lens systems
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
SG11202008399QA (en) 2018-03-12 2020-09-29 Genmab As Antibodies
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
EP3827019A1 (en) 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
JP7241161B2 (ja) * 2018-08-01 2023-03-16 イミュニティーバイオ、インコーポレイテッド 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム
JP2022504802A (ja) * 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド ５ｔ４シングルドメイン抗体およびその治療組成物
GB201911958D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd Methods of t cell production
US20220325336A1 (en) * 2019-09-05 2022-10-13 Bluebird Bio, Inc. Transduction efficiency assay
WO2021072244A1 (en) * 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
JP7789002B2 (ja) 2020-01-29 2025-12-19 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物
CN115484978A (zh) * 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
US12357646B2 (en) 2021-05-14 2025-07-15 Kite Pharma, Inc. Chimeric antigen receptor T cell therapy
JP2025532982A (ja) * 2022-09-28 2025-10-03 スパークス バイオサイエンス リミテッド 白血球免疫グロブリン様受容体サブファミリーｂメンバー２（ｌｉｌｒｂ２）に結合する抗体とその使用
CN117069849B (zh) * 2023-03-21 2024-02-23 武汉奥科博泰生物科技有限公司 识别nag的单克隆抗体及其应用
CN117074674B (zh) * 2023-03-23 2024-01-23 武汉勖瑞生物科技有限责任公司 检测N-乙酰-β-D氨基葡萄糖苷酶的胶体金试纸及其制备方法
CN119074896A (zh) * 2024-10-11 2024-12-06 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) Il-12在制备治疗t-all的药物中的用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
EP0403559A1 (en) 1988-03-04 1990-12-27 Cancer Research Campaign Technology Limited Improvements relating to antigens
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
WO1992003568A1 (en) 1990-08-13 1992-03-05 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
US6852703B1 (en) 1997-06-04 2005-02-08 Oxford Biomedica (Uk) Limited Tumor targeted vector
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
ES2373406T3 (es) 1997-12-22 2012-02-03 Oxford Biomedica (Uk) Limited Vectores basados en el virus de la anemia infecciosa equina (vaie).
GB2370571B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd A modified 5t4 antigen
GB2378704B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd Uses of 5t4 antigen
GB9825303D0 (en) * 1998-11-18 1999-01-13 Oxford Biomedica Ltd Vector
EP1036091B2 (en) 1998-11-18 2008-03-26 Oxford Biomedica (UK) Limited 5t4 tumour-associated antigen for use in tumour immunotherapy
GB9922361D0 (en) 1999-09-21 1999-11-24 Isis Innovation Generating an immune response to an antigen
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
EP1347994A2 (en) 2000-11-13 2003-10-01 Oxford Biomedica (UK) Limited Canine and feline tumour-associated antigen 5t4
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
SI1504108T1 (sl) 2002-02-01 2013-07-31 Oxford Biomedica (Uk) Limited Lentiviralni vektor
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7662625B2 (en) * 2002-07-02 2010-02-16 Cancer Research Technology Limited Methods for detecting the differentiation status of cells using 5T4 antigen expression
GB0215287D0 (en) * 2002-07-02 2002-08-14 Oxford Biomedica Ltd 5T4 antigen expression
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
SV2007002227A (es) * 2004-09-10 2007-03-20 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
CA2606287A1 (en) 2005-05-13 2006-11-16 Oxford Biomedica (Uk) Limited Peptide
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
DK2368914T3 (en) 2006-03-10 2019-03-04 Wyeth Llc Anti-5T4 antibodies and uses thereof
WO2008089053A2 (en) 2007-01-12 2008-07-24 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
WO2009070003A2 (en) 2007-11-30 2009-06-04 Mimos Berhad An analog read out interface circuit for ion sensor
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8642274B2 (en) * 2008-07-15 2014-02-04 Oxford Biomedica, Inc. Immunotherapeutic method
US20120039943A1 (en) 2009-01-09 2012-02-16 Oxford Biomedica (Uk) Limited Factors
WO2010088160A1 (en) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
CA2754610C (en) * 2009-03-27 2015-05-05 Marc Isaac Damelin Tumor-initiating cells and methods for using same
GB0918383D0 (en) * 2009-10-20 2009-12-02 Cancer Rec Tech Ltd Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
CN103124740B (zh) 2010-09-21 2015-09-02 美国卫生和人力服务部 抗-ssx-2t细胞受体和相关材料及使用方法
GB201018480D0 (en) 2010-11-02 2010-12-15 Oxford Biomedica Ltd Factors
WO2012131527A1 (en) 2011-04-01 2012-10-04 Wyeth Llc Antibody-drug conjugates
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
BR112014029417B1 (pt) 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
ES2754397T3 (es) * 2013-10-11 2020-04-17 Asana Biosciences Llc Conjugados de proteína-polímero-fármaco
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
WO2016022939A1 (en) * 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for 5t4 and methods of their use
EP3189073B2 (en) * 2014-09-04 2025-06-11 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
WO2016196388A1 (en) 2015-05-29 2016-12-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
EP3655439A1 (en) * 2017-07-20 2020-05-27 Aptevo Research and Development LLC Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods

Similar Documents

Publication Publication Date Title
JP2020510704A5 (https=)
Zhang et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma
Kirtane et al. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
Alnefaie et al. Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions
CN110475571B (zh) 细胞免疫疗法前细胞毒性预调理的替代
Ottaviano et al. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma
Fan et al. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
Antonia et al. Immuno-oncology combinations: a review of clinical experience and future prospects
Spear et al. NKG2D CAR T‐cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors
Guo et al. Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment
Pabst et al. Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy
Ochi et al. Gene-modified human α/β-T cells expressing a chimeric CD16-CD3ζ receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapy
Pocock et al. Current and emerging therapeutic approaches for T‐cell acute lymphoblastic leukaemia
Kim et al. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics
Dinner et al. Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia
Rosenzweig et al. Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis
Zamagni et al. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
Savani et al. New targets for CAR T therapy in hematologic malignancies
Diorio et al. Harnessing immunotherapy for pediatric T-cell malignancies
Kassner et al. Current landscape of CD3 bispecific antibodies in hematologic malignancies
Sun et al. Macrophages: Targets for next-generation cancer immunotherapy
Sanborn et al. A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors
Pratap et al. Finding new lanes: Chimeric antigen receptor (CAR) T‐cells for myeloid leukemia
CN115850484A (zh) 一种靶向cd70的单链抗体及其应用
Baeuerle et al. T cell engagers emerge as a compelling therapeutic modality